# A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Study · id `cardio:ct-nct05872269` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05872269](<https://clinicaltrials.gov/study/NCT05872269>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05872269

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT05872269. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-20 (actual); primary completion 2025-01-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT05872269, source copy `cardio:ctgov-nct05872269-2024-02-07`, retrieved 2026-10-26)
- Started: 2023-07-20 (actual) (ClinicalTrials.gov record NCT05872269, source copy `cardio:ctgov-nct05872269-2024-02-07`, retrieved 2026-10-26)
- Primary completion: 2025-01-10 (anticipated) (ClinicalTrials.gov record NCT05872269, source copy `cardio:ctgov-nct05872269-2024-02-07`, retrieved 2026-10-26)
- Completion: 2025-06-10 (anticipated) (ClinicalTrials.gov record NCT05872269, source copy `cardio:ctgov-nct05872269-2024-02-07`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT05872269, source copy `cardio:ctgov-nct05872269-2024-02-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05872269-2024-02-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
- Condition: NAFLD
- Condition: Obesity
- Condition: Type 2 Diabetes
- Condition: Dyslipidemias
- Condition: Metabolic Syndrome
- Intervention (Drug): Saroglitazar
- Lead sponsor: Zydus Lifesciences Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Registry condition terms include this condition: Fatty liver disease (NAFLD / MASLD) (`cardio:nafld`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Zydus Lifesciences Limited (`cardio:org-zydus-lifesciences-limited`)

## Provenance

Content hash: 09729b785b90129f3bcbf9198f11bb0d21c164dee545e04be87f7d1e6d9cf97d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
